• Takeda’s Krista McKee on Shifting the Data Ecosystem

    Bio-IT World | Krista McKee’s 20-year career in pharma has steadily taken her on a trajectory toward data science. She is currently Head of Insights and Analytics at Takeda’s Data Sciences Institute (DSI). She recently sat down to discuss how Takeda is recognizing the importance of data alignment and accessibility and the choreography necessary to keep it all moving forward.

    Oct 26, 2021

  • New Discovery Data Architecture Needed to Support New Modalities

    Bio-IT World | Increasingly, the discovery and development of new medicines is embracing bioactive modalities beyond traditional small molecules, both as therapeutic agents and delivery mechanisms. I propose that the industry create standards that describe not only how experimental and substance data should be treated but also cover the services that provide access to that data.

    Oct 22, 2021

  • UC Berkeley, UCSF Launch Computational Precision Health Program

    Bio-IT World | Funded by an anonymous $50 million gift, the University of California, Berkeley and UC San Francisco yesterday announced a joint program in computational precision health.

    Oct 21, 2021

  • Janssen’s Data Ecosystem and the Role of Data Managers

    Bio-IT World | At the Bio-IT World Conference & Expo last month, Aleksandar Stojmirovic and Weiwei Schultz, both of Janssen’s Data Science group, explained the data management mission and vision of Janssen R&D.

    Oct 20, 2021

  • Novel Peptide Drugs Offer Extended Pain Relief

    Bio-IT World | University at Buffalo (UB) researchers plan to commercialize a platform for site-of-injury pain relief that targets nerve endings, the starting point of pain signaling, using lipidated peptides (peptides modified with lipid molecules) that prevent overexcitement of pain neurons.

    Oct 19, 2021

  • Herophilus Aims To ‘Industrialize’ Use Of Organoids For Drug Discovery

    Bio-IT World | A San Francisco-based startup is using robotic automation to “industrialize” the organoid and scale up use of the next-generation human in vitro models in drug discovery experiments for brain diseases. The plan is to use these intact systems, inclusive of microglia as well as neurons, to go after genetically complicated diseases and apply machine learning techniques to find connections between the multi-phenotypic data that gets generated.

    Oct 14, 2021

  • Bio-IT World Issues 2022 Innovative Practices Awards Call for Entries

    Bio-IT World | Bio-IT World is accepting entries for the 2022 Innovative Practices Awards competition. The deadline for entry is March 1, 2022, and the $300 application fee will be waived for entrants who meet the early deadline of January 14, 2022.

    Oct 13, 2021

  • Export Of Damaged Mitochondria To The Heart May Explain ‘Obesity Paradox’

    Bio-IT World | Exosomal trafficking from fat to heart cells may help explain the “obesity paradox,” the baffling observation that packing extra pounds can have a beneficial, if short-term, protective effect for patients with heart disease. The cargo being delivered are oxidatively damaged mitochondrial particles that appear to prompt the heart to produce a flood of protective antioxidant molecules, better preparing it to cope with insults that later come along—such as a heart attack.

    Oct 12, 2021

  • Follow the Money: CRISPR, Next-Gen Neuroscience, Protein Platforms

    Bio-IT World | CRISPR unicorn, pan-coronavirus vaccine research, chemical and biological weapons protection for warfighters, new methods for live cell research, seed round for a new drug discovery platform, and more.

    Oct 11, 2021

  • Amazon Genomics CLI is Open Source, UK Biobank’s Research Analysis Platform Live, More

    Bio-IT World | New leadership at JAX, Illumina expands into Latin America, PacBio partners with The European Reference Genome Atlas, UK Biobank’s Research Analysis Platform is now live, and BC Platforms seeks to build the largest integrated clinical and genomics data biobank in Africa. Plus: new products from MemVerge, Quantum, Pure Storage, Sensyne Health, and more.

    Oct 7, 2021

  • Pistoia Alliance Gauges Life Sciences’ Quantum Computing Outlook

    Bio-IT World | The Pistoia Alliance surveyed life sciences professionals this summer to gauge their understanding of quantum computing. They found that almost half classify their understanding of quantum computing (QC) technology at beginner level only. These results, the Alliance argues, show that despite significant noise around the potential of QC, few life science organizations or individuals are yet able to apply the technology.

    Oct 6, 2021

  • Trends from the Trenches 2021: Where Bio-IT Stands on Digital Transformation, Data Transformation, AI/ML

    Bio-IT World | Chris Dagdigian wasn’t the only speaker at the Bio-IT World Conference & Expo Trends from the Trenches session. He also welcomed Adam Kraut, Karl Gutwin, and Fernanda Foertter—all BioTeam or former BioTeam consultants—to report on trends in digital transformation, data transformation, and AI/ML.

    Oct 5, 2021

  • Speeding Toward Innovation: How Intelligent Search Accelerates Drug Development

    Bio-IT World | Cognitive search—and the intelligence and analytics that go with it—could well be the key element for optimizing innovation and improving the efficiency of research, clinical trials, and regulatory processes.

    Oct 4, 2021

  • NIH Distributes $185M for Impact of Genomic Variation on Function (IGVF) Consortium

    Bio-IT World | At the beginning of September, the National Institutes of Health launched the Impact of Genomic Variation on Function (IGVF) consortium, a new initiative of NIH’s National Human Genome Research Institute (NHGRI). Now, NHGRI has named the first 25 awards across 30 U.S. research sites totaling approximately $185 million over five years.

    Sep 29, 2021

  • Trends in the Trenches 2021: Chris Dagdigian on Security Vaporware, Egnyte, and the Data Management Culture

    Bio-IT World | At this year’s Trends from the Trenches plenary presentation, Chris Dagdigian brought an overview of the trends and a warning of the technology pitfalls facing the Bio-IT community. He continued to beat his drum on a few cultural issues Bio-IT still needs to address, and he alerted the community to what’s new and notable.

    Sep 28, 2021

  • A Pandemic-Driven Digital Transformation: What Will Stick for Life Sciences

    Bio-IT World | Namita Limaye, Research VP at IDC, gave a broad overview of IDC’s survey findings over the past 18 months at this week’s Bio-IT World Conference and Expo held in Boston and online. She highlighted trends in the life sciences that included increased collaboration, speedier adoption of technologies, and a look at how executives are viewing—and planning—digital transformation.

    Sep 23, 2021

  • All of Us Update: Nearing Half a Million Participants, Whole Genomes Available This Winter

    Bio-IT World | Josh Denny, CEO of the All of Us research program, gave an update during the Bio-IT World Conference & Expo this week held in Boston and online.

    Sep 22, 2021

  • Digital Transformation: Execs Weigh in on the New Future for Pharma

    Bio-IT World | The Bio-IT World Conference and Expo kicked off last night both in Boston and online. The hybrid event welcomed attendees in person for the first time since April 2019, starting with an expansive plenary panel on digital transformation—a process that has been kicked into high gear for many companies during the pandemic.

    Sep 21, 2021

  • Enabling Scalability of Cell & Gene Medicines with Connected Lab Cold Storage

    Bio-IT World | Many cell and gene researchers are turning to technology to assist in scaling their operations. Connected and intelligent equipment is also becoming crucial for developers to meet research goals and maintain compliance, including connected ultra-low temperature (ULT) and cryogenic freezers capable of communicating temperature changes, product safety, and more.

    Sep 17, 2021

  • Building an Agile Approach to Antibody Discovery

    Bio-IT World | When the senior leaders at Eli Lilly and Company heard Helen Li’s plan for the pharma’s new Biologica platform for harvesting company institutional knowledge and building an analytic engine to suggest high quality antibody molecules for early discovery pipeline, they had one challenge: do it faster. And so, Li’s team launched an accelerated, agile development plan to build a platform they envisioned to house all experimental data, that feed into in silico modeling, a platform to scale up analytics to empower quality by design.

    Sep 16, 2021